Abstract: The present invention relates to a sprayable formulation comprising live and/or stable bacteria and methods for making such sprayable formulation; in particular in the form of a liquid spray. The invention further relates to the use of this sprayable formulation in human or veterinarian medicine and the use of this sprayable formulation for the prevention and/or treatment of respiratory diseases. The invention further provides methods for the prevention and/or treatment of respiratory diseases.

Abstract: The present invention is directed to a novel isolated bacterial strain of the Streptococcus salivahus (S. salivahus) species. More in particular, a strain of the S. salivahus species deposited at BCCM under accession number LMG P-31813. Further, the present invention relates to a composition comprising an isolated bacterial strain of the S. salivahus species. In another aspect, the present invention further relates to the isolated bacterial strain according to the present invention or the composition according to the present invention for use in immunomodulation and/or in the treatment and/or prevention of infections of diseases.

Abstract: The present invention is directed to a novel isolated bacterial strain of the Lactobacillus casei (L. casei) species. More in particular, the strain of the Lactobacillus casei species deposited under accession number LMG P-30039. The present invention further relates to the novel L. casei strain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novel L. casei strain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novel L. casei strain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of a L. casei species that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of said L.

Abstract: The present invention relates to novel isolated bacterial strains of the Dolosigranulum pigrum species and variants thereof having at least 99% sequence identity in its 16S rRNA gene to said novel strains. The present invention further relates to the use of these bacterial strains, and compositions comprising said strains for use as a probiotic, such as for improving or restoring the flora/microbiota of the respiratory tract and skin. The present invention further relates to the use of these bacterial strains as an antibacterial agent; for use in human or veterinary medicine; for use in the treatment of human or veterinary diseases; or for use in personal hygiene industry, food industry, cleaning industry, pharma industry, or biocontrol applications.

Abstract: The present invention is directed to a novel isolated bacterial strain of the Lactobacillus casei (L. casei) species. More in particular, the strain of the Lactobacillus casei species deposited under accession number LMG P-30039. The present invention further relates to the novel L. casei strain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novel L. casei strain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novel L. casei strain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of a L. casei species that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of said L.